SITC 2021: Preclinical data for SNS-101
Antagonistic pH-selective VISTA antibody SNS-101 potentiates anti-PD-1/PD-L1-induced anti-tumor immunity.
Expanding the range of immunotherapy options has been challenging for a number of reasons, including on-target/off-tumor activity, an immunosuppressive tumor microenvironment, and the cost and time constraints of personalized treatment.
Disables checkpoints and other immunosuppressive signals in the tumor microenvironment to unleash existing T cells against tumors
Trains new T cells to recognize and kill malignant cells